肺動脈高血圧治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Pulmonary Arterial Hypertension - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0898
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:383
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Pulmonary Arterial Hypertension – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension – Pipeline Review, H1 2020, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 15, 12, 2, 40, 10 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 7 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Pulmonary Arterial Hypertension – Overview
Pulmonary Arterial Hypertension – Therapeutics Development
Pulmonary Arterial Hypertension – Therapeutics Assessment
Pulmonary Arterial Hypertension – Companies Involved in Therapeutics Development
Pulmonary Arterial Hypertension – Drug Profiles
Pulmonary Arterial Hypertension – Dormant Projects
Pulmonary Arterial Hypertension – Discontinued Products
Pulmonary Arterial Hypertension – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pulmonary Arterial Hypertension - Pipeline by Aadi Bioscience Inc, H1 2020
Pulmonary Arterial Hypertension - Pipeline by Abivax SA, H1 2020
Pulmonary Arterial Hypertension - Pipeline by Acceleron Pharma Inc, H1 2020
Pulmonary Arterial Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H1 2020
Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, H1 2020
Pulmonary Arterial Hypertension - Dormant Projects, H1 2020
Pulmonary Arterial Hypertension - Discontinued Products, H1 2020

【掲載企業】

Aadi Bioscience Inc
Abivax SA
Acceleron Pharma Inc
Actelion Pharmaceuticals Ltd
Aerogen Ltd
AI Therapeutics
Altavant Sciences Inc
Apaxen
Apollo Therapeutics LLC
APT Therapeutics Inc
Aqualung Therapeutics Corp
ATXA Therapeutics Ltd
AVEO Oncology Inc
Bayer AG
Bial - Portela & Ca SA
Biogen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
C4X Discovery Holdings Plc
Camurus AB
Capricor Therapeutics Inc
Celsion Corp
Celtaxsys Inc
Cereno Scientific AB
Chiesi Farmaceutici SpA
Chugai Pharmaceutical Co Ltd
Complexa Inc
Denovo Biopharma LLC
Eli Lilly and Co
Excubio Pharmaceuticals Inc
Galectin Therapeutics Inc
GenThera Inc
GEXVal Inc
Gilead Sciences Inc
Gmax Biopharm Ltd
Gossamer Bio Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Insmed Inc
Insys Therapeutics Inc
INVENT Pharmaceuticals Inc
Japan Tobacco Inc
Keros Therapeutics Inc
Liquidia Technologies Inc
LTT Bio-Pharma Co Ltd
Martin Pharmaceuticals Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Mifcare
Morphogen-IX Ltd
Nadian Bio Ltd
Nippon Shinyaku Co Ltd
Nissan Chemical Corp
Northern Therapeutics Inc
Novartis AG
Pfizer Inc
Pharmosa Biopharm Inc
PhaseBio Pharmaceuticals Inc
Proteo Inc
Pulmokine Inc
Q BioMed Inc
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
Respira Therapeutics Inc
Resverlogix Corp
Reviva Pharmaceuticals Inc
Schrodinger LLC
Sosei Heptares
SteadyMed Therapeutics Inc
Suda Pharmaceuticals Ltd
Sulfateq BV
Topadur Pharma AG
Translate Bio Inc
Tritech Biopharmaceuticals Co Ltd
United Therapeutics Corp
Vascular BioSciences
Vasculonics LLC
VasThera Research Institute
Velocity Pharmaceutical Development LLC
Vivus Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[肺動脈高血圧治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆